Dementia

The main purpose of this study is to track the cognitive, lifestyle and psychological markers of a large group of community-based middle-aged adults (40-65 years inclusive) over five years online, in relation to genetic risk factors that are shown to increase risk of Alzheimer’s disease dementia in older adults.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Colitis and Crohn's Disease

Crohn’s disease is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgotinib, an experimental drug, is effective and safe in treating people with moderate to severe Crohn’s disease.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cancer - Breast

Denosumab is approved for use in osteoporosis. Laboratory research has identified other potential effects, including possibly slowing or stopping breast cell growth. The BRCA-D trial aims to investigate the effects of denosumab on normal breast tissue in patients with BRCA 1 or 2 mutations and to determine if the drug has potential to prevent breast cancer. Breast tissue will be obtained and evaluated before and after the denosumab injections.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Neurological - Multiple sclerosis

We are seeking to examine the effectiveness of a tailored cognitive behaviour (CBT) therapy based psychological intervention for the treatment of depression in people newly diagnosed with multiple sclerosis. CBT is a type of "talk therapy" that helps people learn new skills targeting their thinking and behaviour often used for the treatment of depression, anxiety.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

Research has shown a relationship between higher levels of brain iron, the presence of the Alzheimer’s protein, amyloid, and poorer memory and language skills. The purpose of this study is to test the effects of Deferiprone on your disease.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

This study aims to see how effective a new blood test (using a diagnostic test called EUROIMMUN biochip) is in diagnosing and monitoring autoimmune blistering skin diseases, in comparison to the standard blood test.

Participants will be asked to donate an additional sample of blood which will be used for research into genetic susceptibility to autoimmune blistering skin disease. Only one visit is required and this usually will occur at the time of your visit at The Royal Melbourne Hospital.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

The research study is testing a new treatment for vascular dementia (VaD) and Alzheimer’s disease with cerebrovascular disease. The new treatment is called Sailuotong (SLT). SLT is an extract of three standardised Chinese herbs, Ginseng, Ginkgo and Saffron, all of which are individually permitted for over-the-counter sale in Australia.

The primary objective is to determine the effectiveness of the herbal intervention on cognitive function (the brain functions relating to attention, memory, judgement, reasoning, problem solving etc.), activities of daily living and quality of life, and monitor the safety and effectiveness of SLT.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Diabetes (Type 1)

Diabetic kidney disease is an important health challenge. There is a great need to develop new treatment strategies because, even with current treatments, there may be progressive decrease in kidney function. This could lead to kidney failure needing dialysis or kidney transplantation. In one form of diabetic kidney disease, there is leakage of abnormal amounts of protein into the urine (called “albuminuria”). The study drug is aimed at lowering urinary albumin leak and to slow down the decrease of kidney function associated with diabetic kidney disease. In summary we are testing whether a new tablet can help to treat diabetic kidney disease.

Participants will randomly be allocated to receive either the new tablet or a placebo. This is a double-blind study which means that neither you nor your study doctor will know which treatment you are receiving. The project is designed this way to ensure that researchers interpret the results in a fair and appropriate way and avoids study doctors or participants jumping to conclusions.

Anticipated date enrolment will close: 31 December 2021

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4